初治肝细胞癌患者血浆游离DNA基因谱分析的初步研究
该前瞻性初步研究同步采集30例未接受系统治疗的肝细胞癌患者的肿瘤活检和血浆,用靶向46个基因的深度测序比较组织DNA与cfDNA的突变谱。结果显示63%患者cfDNA可检出HCC相关体细胞突变,27%可无活检信息de novo检出,且突变负荷与肿瘤大小和Edmondson分级正相关。在肿瘤≥5cm或转移的7例患者中,86%可de novo检出突变,提示高疾病负荷时cfDNA基因分型可行。
要点
- 初治HCC患者cfDNA可检出63%的HCC相关体细胞突变。
- 27%患者cfDNA可无活检信息de novo检出突变。
- 肿瘤≥5cm或转移者cfDNA de novo检出率达86%。
核心结论
- 在高疾病负荷的初治HCC患者中,当活检不可及时,使用cfDNA进行基因谱分析可能是可行的。
- 结果支持在更大队列中进一步研究cfDNA的临床效用。
研究设计与样本
- 前瞻性初步研究,同步采集30例未接受系统治疗的HCC患者的原发肿瘤冷冻活检和血浆。
- 对活检DNA、血浆cfDNA和匹配胚系DNA进行靶向46个编码和非编码基因的深度测序。
主要发现
- 26/30例患者在活检和/或cfDNA中至少检出1个体细胞突变。
- 63%(19/30)患者cfDNA中存在HCC相关基因的体细胞突变。
- 27%(8/30)患者可在不知活检突变的情况下de novo检出cfDNA突变。
- cfDNA中突变负荷和变异等位基因频率与肿瘤大小和Edmondson分级正相关。
- 在最大肿瘤≥5cm或伴转移的7例患者中,86%(6/7)cfDNA可de novo检出至少1个突变。
关键数值与推荐
- 在最大肿瘤≥5cm或伴转移的7例患者中,cfDNA和肿瘤DNA分别捕获87%(80/92)和95%(87/92)的突变。
临床怎么用
- 对于高疾病负荷且活检不可及的初治HCC患者,可考虑用血浆cfDNA进行基因谱分析。
- cfDNA基因分型结果需结合肿瘤负荷解读,低负荷患者de novo检出率有限。
局限性
- 本研究为初步研究,样本量仅30例。
- 结论需在更大队列中进一步验证cfDNA的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinomas (HCCs) are not routinely biopsied, resulting in a lack of tumor materials for molecular profiling. Here we sought to determine whether plasma-derived cell-free DNA (cfDNA) captures the genetic alterations of HCC in patients who have not undergone systemic therapy. PATIENTS AND METHODS: Frozen biopsies from the primary tumor and plasma were synchronously collected from 30 prospectively recruited, systemic treatment-naïve HCC patients. Deep sequencing of the DNA from the biopsies, plasma-derived cfDNA and matched germline was carried out using a panel targeting 46 coding and non-coding genes frequently altered in HCCs. RESULTS: In 26/30 patients, at least one somatic mutation was detected in biopsy and/or cfDNA. Somatic mutations in HCC-associated genes were present in the cfDNA of 63% (19/30) of the patients and could be detected 'de novo' without prior knowledge of the mutations present in the biopsy in 27% (8/30) of the patients. Mutational load and the variant allele fraction of the mutations detected in the cfDNA positively correlated with tumor size and Edmondson grade. Crucially, among the seven patients in whom the largest tumor was ≥5 cm or was associated with metastasis, at least one mutation was detected 'de novo' in the cfDNA of 86% (6/7) of the cases. In these patients, cfDNA and tumor DNA captured 87% (80/92) and 95% (87/92) of the mutations, suggesting that cfDNA and tumor DNA captured similar proportions of somatic mutations. CONCLUSION: In patients with high disease burden, the use of cfDNA for genetic profiling when biopsy is unavailable may be feasible. Our results support further investigations into the clinical utility of cfDNA in a larger cohort of patients.
引用
- Ng CKY, Di Costanzo GG, Tosti N, et al. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol. 2018. PMID: 29509837. doi:10.1093/annonc/mdy083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。